November 10, 2025 — Leads & Copy — Avid Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), has appointed Dave Stewart as Chief Technology and Transformation Officer, a newly created role to advance the company’s next phase of growth and evolution. The announcement was made today.
The addition of this role is an important step in CEO Kenneth Bilenberg’s strategy to position Avid for continued expansion, ensuring the company is reliable, predictable, and proactive at every stage.
Bilenberg stated that Avid has built tremendous momentum over the past several years, and the company is making deliberate investments in people, processes, and systems to power its future. He expressed confidence in Stewart’s expertise and integrity, noting his leadership will support the company’s vision to be the easiest external partner to work with while expanding its capabilities for clients and their patients.
In his new role, Stewart will lead the integration of technology and process transformation initiatives across Avid’s development and manufacturing network. His focus will include digital modernization, automation, and integration of advanced tools and service capabilities. He will work closely with Avid’s team to ensure the company’s systems and platforms enable greater efficiency, alignment, and flexibility as the organization expands.
Stewart expressed admiration for Avid’s reputation for quality and its focus on patients. He noted the team’s commitment to doing things the right way and said that joining Avid at this dynamic point in its growth is a tremendous opportunity to contribute to a mission he believes in.
The addition of the CTTO role underscores Avid’s commitment to continuous improvement and client partnership, ensuring the company remains agile and future-ready as it expands capacity and capabilities across its facilities.
Avid Bioservices specializes in mammalian cell-culture manufacturing. Headquartered in the U.S. with a flawless FDA record, Avid is trusted by biopharmaceutical innovators for its agility, quality, and ability to navigate complex global regulatory landscapes, providing end-to-end solutions from development through commercial supply.
Avid By The Numbers:
More than 600 batches manufactured
Over 275 commercial batches delivered globally
6+ approved commercial products
10 successful pre-approval/pre-license inspections across major regulatory agencies
Contact:
Avid Bioservices, Inc.
Source: Avid Bioservices, Inc.
Source: Avid Bioservices, Inc.
